Australia’s active vaccine safety system

Data on this page show the responses of individuals aged 5-11 years who received the paediatric 10 microgram formulation of the Pfizer COVID-19 vaccine and whose parent or carer completed an AusVaxSafety survey on their child's behalf sent on day 3 after vaccination. These data provide you with a profile of what to expect in the days following your child's Pfizer COVID-19 vaccination and can assist when planning for your child's COVID-19 vaccination.

Have you been diagnosed with myocarditis following COVID-19 vaccination?

Enrol in the AusVaxSafety long-term follow-up program to help Australia better understand the long-term effects of myocarditis following COVID-19 vaccination.

Click here to enrol or learn more

 

The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.

AusVaxSafety's active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration (TGA). Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.

Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.

Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: 

AusVaxSafety will continue to closely monitor the safety data of all COVID-19 vaccines in use in Australia in conjunction with the TGA.